SynthesisBMC cancer2015
Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis.
Synthesis in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Melanoma of the external auditory canal: case report and systematic literature review.Pathologica · 2024Pooled it
- Head and Neck Mucosal Melanoma in the Era of Immunotherapy: A National Cancer Database Review.Head & neck · 2026Article
- Primary malignant melanoma of the female urethra: a case report and literature review.The Canadian journal of urology · 2026Review
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Stemness and Survival: CD117Cells · 2026Article
- Sinonasal mucosal melanoma in an elderly patient: a case report.Journal of medical case reports · 2025Article
- Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy.Head & neck · 2025Article
- Primary Sinonasal Mucosal Melanoma: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Article
- Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.JCI insight · 2024Article
- Review
- Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.Current oncology (Toronto, Ont.) · 2024Article
- Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution.Laryngoscope investigative otolaryngology · 2023Article
- CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.Molecular cancer · 2023Review
- Mucosal Melanoma of the Oral Cavity: What is the Role of Elective Neck Dissection?The Laryngoscope · 2023Article
- Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.Gynecologic oncology · 2022Article
- Evolving Treatment Approaches to Mucosal Melanoma.Current oncology reports · 2022Review
- Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma.The Laryngoscope · 2022Article
- Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Patients with Head and Neck Mucosal Melanoma.International journal of general medicine · 2022Article
- Expression and clinical significance of TYRP1, ABCB5, and MMP17 in sinonasal mucosal melanoma.Cancer biomarkers : section A of Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck mucosal melanoma (HNMM) is a rare type of malignant tumor that frequently exhibits postoperative recurrence and distant metastasis. Many clinicians administer postoperative adjuvant radiotherapy to improve patient prognosis and enhance quality of life; however, the effects of this treatment remain controversial. Therefore, in this study, a meta-analysis was performed to evaluate the practical value of postoperative adjuvant radiotherapy for head and neck mucosal melanoma.
methodsArticles in the PubMed, MEDLINE, Cochrane Library, Web of Science and EMBASE databases were systematically retrieved. Analyses were conducted to compare the impact of treatments involving postoperative radiotherapy with treatments entailing surgery alone on patient overall survival time, local recurrence and distant metastasis. The hazard ratio (HR) was used to evaluate the time-to-event data employing RevMan version 5.2 and Stata/SE version 13.0 software according to the principles specified for systematic reviews of interventions in the Cochrane handbook.
resultsTwelve cohort studies involving 1593 patients satisfied the desired conditions. In comparing surgery alone with postoperative radiotherapy, there was no significant difference regarding a decrease in the death risk in HNMM patients (HR, 1.07; 95 % CI, 0.95-1.2; p = 0.903; low heterogeneity, I(2) = 0); this was also the case for sinonasal melanoma after subgroup meta-analysis (HR, 1.04; 95 % CI, 0.8-1.36; p = 0.983; low heterogeneity, I(2) = 0 %). A sensitivity analysis and subgroup meta-analysis showed that disease progression was the main source of the instability in the results. Surgery combined with postoperative radiotherapy reduced the risk of local recurrence (HR, 0.51; 95 % CI, 0.35-0.76; p = 0.155) but did not reduce the risk of distant metastasis (HR, 2.26; 95 % CI, 1.01-5.05; p = 0.006).
conclusionsThis study demonstrated that for HNMM patients surgery is recommended if indicated, and surgery combined with postoperative radiotherapy is also recommended for dramatically improved local control of the tumor bed. For patients not suitable for surgical treatment, radiotherapy is still advised. To control distant metastasis and finally lower the risk of death, immunological therapy is another potential option whose therapeutic effect needs to be proved with more data from clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.